The approval follows the CHMP's reversal of a previous decision not to recommend the drug, instead recommending it with certain restrictions.
In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...
In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.
The approval includes patients whose disease progressed after treatment with endocrine therapy, which can cause ESR1 mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback